

# Patrice Andr ©

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5188606/publications.pdf>

Version: 2024-02-01

137  
papers

6,950  
citations

53794

45  
h-index

64796

79  
g-index

141  
all docs

141  
docs citations

141  
times ranked

9730  
citing authors

#	ARTICLE	IF	CITATIONS
1	Domain 2 of Hepatitis C Virus Protein NS5A Activates Glucokinase and Induces Lipogenesis in Hepatocytes. <i>International Journal of Molecular Sciences</i> , 2022, 23, 919.	4.1	7
2	A hexokinase isoenzyme switch in human liver cancer cells promotes lipogenesis and enhances innate immunity. <i>Communications Biology</i> , 2021, 4, 217.	4.4	21
3	Farnesoid X receptor agonist for the treatment of chronic hepatitis B: A safety study. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1690-1698.	2.0	21
4	The current landscape of coronavirus-host protein-protein interactions. <i>Journal of Translational Medicine</i> , 2020, 18, 319.	4.4	66
5	Farnesoid X receptor alpha ligands inhibit hepatitis delta virus replication in vitro independently of their effect on hepatitis B virus. <i>Journal of Hepatology</i> , 2020, 73, S834-S835.	3.7	0
6	Farnesoid X receptor is a proviral host factor for hepatitis B virus that is inhibited by ligands in vitro and in vivo. <i>FASEB Journal</i> , 2019, 33, 2472-2483.	0.5	33
7	Structural Studies of Self-Assembled Subviral Particles: Combining Cell-Free Expression with 110 kHz MAS NMR Spectroscopy. <i>Angewandte Chemie - International Edition</i> , 2018, 57, 4787-4791.	13.8	37
8	What Is the most Important for Elite Control: Genetic Background of Patient, Genetic Background of Partner, both or neither? Description of Complete Natural History within a Couple of MSM. <i>EBioMedicine</i> , 2018, 27, 51-60.	6.1	8
9	First clinical evaluation in chronic hepatitis B patients of the synthetic farnesoid X receptor agonist EYP001. <i>Journal of Hepatology</i> , 2018, 68, S488-S489.	3.7	9
10	Metabolic rewiring and de novo lipogenesis induced by Glucokinase expression in hepatocarcinoma cell line. <i>Journal of Hepatology</i> , 2018, 68, S139.	3.7	0
11	Control of glycokinase activity by the HCV protein NS5A increases lipogenesis. <i>Journal of Hepatology</i> , 2018, 68, S779.	3.7	0
12	Toll-like Receptor 4-Induced Glycolytic Burst in Human Monocyte-Derived Dendritic Cells Results from p38-Dependent Stabilization of HIF-1 and Increased Hexokinase II Expression. <i>Journal of Immunology</i> , 2018, 201, 1510-1521.	0.8	55
13	FXR is a proviral factor whose binding to HBV genome is modulated by FXR agonist and correlates with presence of the activated chromatin mark H3K4me3 in an HBx dependant manner. <i>Journal of Hepatology</i> , 2018, 68, S773.	3.7	0
14	FXR agonist GW4064 represses HBV replication in adult but not in young C3H/HeN mice after HBV transduction with rAAV2/8-HBV. <i>Journal of Hepatology</i> , 2018, 68, S780.	3.7	0
15	Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen. <i>Clinical Infectious Diseases</i> , 2018, 66, 1588-1594.	5.8	15
16	TLR4 antagonist FP7 inhibits LPS-induced cytokine production and glycolytic reprogramming in dendritic cells, and protects mice from lethal influenza infection. <i>Scientific Reports</i> , 2017, 7, 40791.	3.3	105
17	Comparison of HIV-1 drug-resistance genotyping by ultra-deep sequencing and sanger sequencing using clinical samples. <i>Journal of Medical Virology</i> , 2017, 89, 1912-1919.	5.0	14
18	An early step of hepatitis B virus infection is dependent on the nuclear receptor for bile acids, farnesoid X receptor alpha. <i>Journal of Hepatology</i> , 2017, 66, S697-S698.	3.7	0

#	ARTICLE	IF	CITATIONS
19	Deleterious impact of C3d-binding donor-specific anti-HLA antibodies after pediatric liver transplantation. <i>Transplant Immunology</i> , 2017, 45, 8-14.	1.2	21
20	Natural non-homologous recombination led to the emergence of a duplicated V3-NS5A region in HCV-1b strains associated with hepatocellular carcinoma. <i>PLoS ONE</i> , 2017, 12, e0174651.	2.5	1
21	Hepatitis E virus mutations associated with ribavirin treatment failure result in altered viral fitness and ribavirin sensitivity. <i>Journal of Hepatology</i> , 2016, 65, 499-508.	3.7	99
22	Evolution of the incidence of hepatitis B virus infection and immunization rates in a large French cohort born between 1960 and 1994. <i>Clinical Microbiology and Infection</i> , 2016, 22, 889.e1-889.e7.	6.0	8
23	HIV-1 sequences isolated from patients promote expression of shorter isoforms of the Gag polyprotein. <i>Archives of Virology</i> , 2016, 161, 3495-3507.	2.1	7
24	Maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy with tenofovir/emtricitabine/maraviroc/raltegravir in treatment-naive HIV patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3235-3241.	3.0	1
25	Reciprocal regulation of farnesoid X receptor $\hat{\pm}$ activity and hepatitis B virus replication in differentiated HepaRG cells and primary human hepatocytes. <i>FASEB Journal</i> , 2016, 30, 3146-3154.	0.5	30
26	A case of Mayaro virus infection imported from French Guiana. <i>Journal of Clinical Virology</i> , 2016, 77, 66-68.	3.1	58
27	P209: Near full-length hepatitis E virus genome sequencing analysis in a chronically infected patient following ribavirin treatment failure. <i>Journal of Viral Hepatitis</i> , 2015, 22, 124-125.	2.0	2
28	Duplex High-Resolution Melting Assay for the Simultaneous Genotyping of IL28B rs12979860 and PNPLA3 rs738409 Polymorphisms in Chronic Hepatitis C Patients. <i>International Journal of Molecular Sciences</i> , 2015, 16, 22223-22242.	4.1	4
29	HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc. <i>PLoS ONE</i> , 2015, 10, e0127816.	2.5	3
30	Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1507-1512.	3.0	52
31	Identification of a duplicated V3 domain in NS5A associated with cirrhosis and hepatocellular carcinoma in HCV-1b patients. <i>Journal of Clinical Virology</i> , 2015, 69, 203-209.	3.1	6
32	HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007-2012: impact on susceptibility to first-line strategies. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2084-2089.	3.0	42
33	Antiretroviral-naive and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 566-572.	3.0	8
34	Persistent Production of an Integrase-Deleted HIV-1 Variant with No Resistance Mutation and Wild-Type Proviral DNA in a Treated Patient. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 142-149.	1.1	5
35	Virus-host interactomics: new insights and opportunities for antiviral drug discovery. <i>Genome Medicine</i> , 2014, 6, 115.	8.2	85
36	Circulating RNA Molecules as Biomarkers in Liver Disease. <i>International Journal of Molecular Sciences</i> , 2014, 15, 17644-17666.	4.1	50

#	ARTICLE	IF	CITATIONS
37	Acute hepatitis C with evidence of heterosexual transmission: A new case. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2014, 38, e51-e54.	1.5	0
38	Hepatitis E in liver transplant recipients in the Rhône-Alpes region in France. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2014, 33, 1037-1043.	2.9	27
39	The metabolic sensors FXR $\pm$ , PGC $\alpha$ 1 $\pm$ , and SIRT1 cooperatively regulate hepatitis B virus transcription. <i>FASEB Journal</i> , 2014, 28, 1454-1463.	0.5	40
40	High burden of BK virus-associated hemorrhagic cystitis in patients undergoing allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2014, 49, 664-670.	2.4	123
41	Association between discordant immunological response to highly active anti-retroviral therapy, regulatory T cell percentage, immune cell activation and very low-level viraemia in HIV-infected patients. <i>Clinical and Experimental Immunology</i> , 2014, 176, 401-409.	2.6	27
42	Activity of Hexokinase Is Increased by Its Interaction with Hepatitis C Virus Protein NS5A. <i>Journal of Virology</i> , 2014, 88, 3246-3254.	3.4	88
43	Recent evidence of underestimated circulation of hepatitis C virus intergenotypic recombinant strain RF2k/1b in the Rhône-Alpes region, France, January to August 2014: implications for antiviral treatment. <i>Eurosurveillance</i> , 2014, 19, .	7.0	14
44	Hepatitis C virus/human interactome identifies SMURF2 and the viral protease as critical elements for the control of TGF $\beta$ <sup>2</sup> signaling. <i>FASEB Journal</i> , 2013, 27, 4027-4040.	0.5	16
45	916 BOCEPREVIR AND TELAPREVIR BASED TRIPLE THERAPY FOR CHRONIC HEPATITIS C: ON-TREATMENT EFFICACY AND IMPACT ON KIDNEY FUNCTION AND MELD SCORE. <i>Journal of Hepatology</i> , 2013, 58, S377-S378.	3.7	0
46	Structure homology and interaction redundancy for discovering virus-host protein interactions. <i>EMBO Reports</i> , 2013, 14, 938-944.	4.5	39
47	Modified lipoproteins provide lipids that modulate dendritic cell immune function. <i>Biochimie</i> , 2013, 95, 103-108.	2.6	28
48	1217 EXPERIENCE OF HCV RESISTANCE AFTER 1.5 YEARS CLINICAL PRACTICE; DETECTION OF RESISTANCE MUTATIONS AFTER LONG PERIOD OF UNDETECTABILITY. <i>Journal of Hepatology</i> , 2013, 58, S494-S495.	3.7	0
49	Complications and factors associated with severity of influenza in hospitalized children and adults during the pandemic wave of A(H1N1)pdm2009 infections-The Fluco French cohort. <i>Journal of Clinical Virology</i> , 2013, 58, 114-119.	3.1	6
50	A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure. <i>International Journal of Antimicrobial Agents</i> , 2013, 42, 42-47.	2.5	19
51	Real-life evaluation of a human immunodeficiency virus screening algorithm using a single combined p24 antigen-antibody assay. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2013, 32, 425-430.	2.9	15
52	Low-level viremia is associated with non-B subtypes in patients infected with HIV with virological success following HAART introduction. <i>Journal of Medical Virology</i> , 2013, 85, 953-958.	5.0	9
53	The Interactomes of Influenza Virus NS1 and NS2 Proteins Identify New Host Factors and Provide Insights for ADAR1 Playing a Supportive Role in Virus Replication. <i>PLoS Pathogens</i> , 2013, 9, e1003440.	4.7	91
54	HIV-1 Dynamics and Coreceptor Usage in Maraviroc-Treated Patients with Ongoing Replication. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 930-935.	3.2	16

#	ARTICLE	IF	CITATIONS
55	National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2626-2631.	3.0	41
56	Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL in 2009: a French nationwide study. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1400-1405.	3.0	29
57	Mapping of Chikungunya Virus Interactions with Host Proteins Identified nsP2 as a Highly Connected Viral Component. <i>Journal of Virology</i> , 2012, 86, 3121-3134.	3.4	98
58	Different effects of the TAR structure on HIV-1 and HIV-2 genomic RNA translation. <i>Nucleic Acids Research</i> , 2012, 40, 2653-2667.	14.5	38
59	Viruses and Interactomes in Translation. <i>Molecular and Cellular Proteomics</i> , 2012, 11, M111.014738-1-M111.014738-12.	3.8	44
60	Farnesoid X Receptor Targeting for Hepatitis C: Study Protocol for a Proof-of-concept Trial. <i>Therapie</i> , 2012, 67, 423-427.	1.0	3
61	New horizons for antiviral drug discovery from virus-host protein interaction networks. <i>Current Opinion in Virology</i> , 2012, 2, 606-613.	5.4	53
62	Human group X secreted phospholipase A2 induces dendritic cell maturation through lipoprotein-dependent and -independent mechanisms. <i>Atherosclerosis</i> , 2012, 222, 367-374.	0.8	14
63	Genetic screens for the control of influenza virus replication: from meta-analysis to drug discovery. <i>Molecular BioSystems</i> , 2012, 8, 1297.	2.9	30
64	Standardized One-Step Real-Time Reverse Transcription-PCR Assay for Universal Detection and Quantification of Hepatitis Delta Virus from Clinical Samples in the Presence of a Heterologous Internal-Control RNA. <i>Journal of Clinical Microbiology</i> , 2012, 50, 2126-2128.	3.9	28
65	Seroprevalence of hepatitis E virus infection in rural and urban populations, Tunisia. <i>Clinical Microbiology and Infection</i> , 2012, 18, E119-E121.	6.0	17
66	High-density lipoprotein phospholipids interfere with dendritic cell Th1 functional maturation. <i>Immunobiology</i> , 2012, 217, 91-99.	1.9	28
67	High plasma level of nucleocapsid-free envelope glycoprotein-positive lipoproteins in hepatitis C patients. <i>Hepatology</i> , 2012, 56, 39-48.	7.3	48
68	<i>in vitro</i> studies reveal that different modes of initiation on HIV-1 mRNA have different levels of requirement for eukaryotic initiation factor eIF4F. <i>FEBS Journal</i> , 2012, 279, 3098-3111.	4.7	30
69	Discordance in HIV-1 Co-receptor use prediction by different genotypic algorithms and phenotype assay: Intermediate profile in relation to concordant predictions. <i>Journal of Medical Virology</i> , 2012, 84, 402-413.	5.0	12
70	HIV-1 Load Comparison Using Four Commercial Real-Time Assays. <i>Journal of Clinical Microbiology</i> , 2011, 49, 292-297.	3.9	54
71	Role of nuclear receptors in hepatitis B and C infections. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, 169-175.	1.5	3
72	Assembly of infectious hepatitis C virus particles. <i>Trends in Microbiology</i> , 2011, 19, 95-103.	7.7	389

#	ARTICLE	IF	CITATIONS
73	Triacylglycerol biosynthesis: another cellular lipid pathway essential to HCV replication. <i>Future Virology</i> , 2011, 6, 179-182.	1.8	0
74	Flavivirus NS3 and NS5 proteins interaction network: a high-throughput yeast two-hybrid screen. <i>BMC Microbiology</i> , 2011, 11, 234.	3.3	91
75	Generation and Comprehensive Analysis of an Influenza Virus Polymerase Cellular Interaction Network. <i>Journal of Virology</i> , 2011, 85, 13010-13018.	3.4	69
76	Improved V3 genotyping with duplicate PCR amplification for determining HIV-1 tropism. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1972-1975.	3.0	14
77	Biochemical and Morphological Properties of Hepatitis C Virus Particles and Determination of Their Lipidome. <i>Journal of Biological Chemistry</i> , 2011, 286, 3018-3032.	3.4	308
78	IRGM Is a Common Target of RNA Viruses that Subvert the Autophagy Network. <i>PLoS Pathogens</i> , 2011, 7, e1002422.	4.7	173
79	Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naïve chronically HIV-infected patients from 2001 to 2006/2007 in France. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2620-2627.	3.0	62
80	Morphological Characterization and Fusion Properties of Triglyceride-rich Lipoproteins Obtained from Cells Transduced with Hepatitis C Virus Glycoproteins. <i>Journal of Biological Chemistry</i> , 2010, 285, 25802-25811.	3.4	13
81	Drug-resistant cytomegalovirus in transplant recipients: a French cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2628-2640.	3.0	141
82	Measuring human immunodeficiency virus type 1 RNA loads in dried blood spot specimens using NucliSENS EasyQ HIV-1 v2.0. <i>Journal of Clinical Virology</i> , 2010, 47, 120-125.	3.1	43
83	System-Level Comparison of Protein-Protein Interactions between Viruses and the Human Type I Interferon System Network. <i>Journal of Proteome Research</i> , 2010, 9, 3527-3536.	3.7	29
84	Prediction of the virological response to etravirine in clinical practice: Comparison of three genotype algorithms. <i>Journal of Medical Virology</i> , 2009, 81, 672-677.	5.0	18
85	Clearance of serum HBsAg and anti-HBs seroconversion following antiviral therapy for chronic hepatitis B. <i>Journal of Medical Virology</i> , 2009, 81, 1336-1342.	5.0	34
86	VirHostNet: a knowledge base for the management and the analysis of proteome-wide virus-host interaction networks. <i>Nucleic Acids Research</i> , 2009, 37, D661-D668.	14.5	140
87	Sexually transmitted HCV infection and reinfection in HIV-infected homosexual men. <i>Gastroenterologie Clinique Et Biologique</i> , 2009, 33, 977-980.	0.9	13
88	Secretion of Hepatitis C Virus Envelope Glycoproteins Depends on Assembly of Apolipoprotein B Positive Lipoproteins. <i>PLoS ONE</i> , 2009, 4, e4233.	2.5	118
89	Transmission of low-density hepatitis C viral particles during sexually transmitted acute resolving infection. <i>Journal of Medical Virology</i> , 2008, 80, 242-246.	5.0	12
90	Natural polymorphisms in HIV-1 protease: Impact on effectiveness of a first-line lopinavir-containing antiretroviral therapy regimen. <i>Journal of Medical Virology</i> , 2008, 80, 1871-1879.	5.0	12

#	ARTICLE	IF	CITATIONS
91	Effect of early initiation of highly active antiretroviral therapy on CD4 cell count and HIVâ€RNA viral load trends within 24 months of the onset of acute retroviral syndrome<sup>*</sup>. HIV Medicine, 2008, 9, 440-444.	2.2	7
92	Hepatitis C virus infection protein network. Molecular Systems Biology, 2008, 4, 230.	7.2	340
93	Enhancement of genotype 1 hepatitis C virus replication by bile acids through FXR. Journal of Hepatology, 2008, 48, 192-199.	3.7	62
94	Hepatitis C virus assembly: When fat makes it easier. Journal of Hepatology, 2008, 49, 153-155.	3.7	2
95	Transactivation of the Hepatitis B Virus Core Promoter by the Nuclear Receptor FXR±. Journal of Virology, 2008, 82, 10832-10840.	3.4	78
96	Expected response to protease inhibitors of HIV-1 non-B subtype viruses according to resistance algorithms. Aids, 2008, 22, 1087-1089.	2.2	13
97	Th1 Disabled Function in Response to TLR4 Stimulation of Monocyte-Derived DC from Patients Chronically-Infected by Hepatitis C Virus. PLoS ONE, 2008, 3, e2260.	2.5	30
98	Variants With Different Mutation Patterns Persist in the Quasispecies of Enfuvirtide-Resistant HIV-1 Population During and After Treatment In Vivo. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 46, 134-144.	2.1	7
99	Human Polycomb group EED protein negatively affects HIV-1 assembly and release. Retrovirology, 2007, 4, 37.	2.0	10
100	Hepatitis C Lipo-Viro-Particle from Chronically Infected Patients Interferes with TLR4 Signaling in Dendritic Cell. PLoS ONE, 2007, 2, e330.	2.5	25
101	Lysophosphatidylcholine is a natural adjuvant that initiates cellular immune responses. Vaccine, 2006, 24, 1254-1263.	3.8	50
102	1-Methyl-Tryptophan Can Interfere with TLR Signaling in Dendritic Cells Independently of IDO Activity. Journal of Immunology, 2006, 177, 2061-2071.	0.8	80
103	Preferential association of Hepatitis C virus with apolipoprotein B48-containing lipoproteins. Journal of General Virology, 2006, 87, 2983-2991.	2.9	91
104	French National Sentinel Survey of Antiretroviral Drug Resistance in Patients With HIV-1 Primary Infection and in Antiretroviral-Naive Chronically Infected Patients in 2001-2002. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 38, 545-552.	2.1	110
105	Hepatitis C Virus Particles and Lipoprotein Metabolism. Seminars in Liver Disease, 2005, 25, 93-104.	3.6	163
106	Expression of hepatitis C virus proteins in epithelial intestinal cells in vivo. Journal of General Virology, 2004, 85, 2515-2523.	2.9	52
107	Sensing Environmental Lipids by Dendritic Cell Modulates Its Function. Journal of Immunology, 2004, 172, 54-60.	0.8	52
108	Strand specific quantitative real-time PCR to study replication of hepatitis C virus genome. Journal of Virological Methods, 2004, 116, 103-106.	2.1	75

#	ARTICLE	IF	CITATIONS
109	Secretory phospholipase A2 induces dendritic cell maturation. <i>European Journal of Immunology</i> , 2004, 34, 2293-2302.	2.9	62
110	Failure and success of HIV tests for the prevention of HIV-1 transmission by blood and tissue donations. <i>Journal of Medical Virology</i> , 2004, 73, 347-349.	5.0	27
111	Effects of the proteasome inhibitor ritonavir on glioma growth in vitro and in vivo. <i>Molecular Cancer Therapeutics</i> , 2004, 3, 129-36.	4.1	48
112	Mature Dendritic Cell Generation Promoted by Lysophosphatidylcholine. <i>Journal of Immunology</i> , 2002, 169, 1688-1695.	0.8	81
113	Characterization of Low- and Very-Low-Density Hepatitis C Virus RNA-Containing Particles. <i>Journal of Virology</i> , 2002, 76, 6919-6928.	3.4	584
114	Protection against experimental autoimmune encephalomyelitis by a proteasome modulator. <i>Journal of Neuroimmunology</i> , 2001, 118, 233-244.	2.3	26
115	Quantitation of HCV RNA using real-time PCR and fluorimetry. <i>Journal of Virological Methods</i> , 2001, 95, 111-119.	2.1	93
116	Oxidized Low-Density Lipoprotein Promotes Mature Dendritic Cell Transition from Differentiating Monocyte. <i>Journal of Immunology</i> , 2001, 167, 3785-3791.	0.8	133
117	Modulation of HLA-G Antigens Expression by Human Cytomegalovirus: Specific Induction in Activated Macrophages Harboring Human Cytomegalovirus Infection. <i>Journal of Immunology</i> , 2000, 164, 6426-6434.	0.8	151
118	Modulation of HLA-G antigens expression in myelomonocytic cells. <i>Human Immunology</i> , 2000, 61, 1086-1094.	2.4	48
119	Interferon and ursodeoxycholic acid combined therapy in chronic viral C hepatitis: controlled randomized trial in 203 patients. <i>Digestive and Liver Disease</i> , 2000, 32, 29-33.	0.9	9
120	Molecular Cloning of a Lipolysis-stimulated Remnant Receptor Expressed in the Liver. <i>Journal of Biological Chemistry</i> , 1999, 274, 13390-13398.	3.4	61
121	A Pilot Study of Iron Depletion As Adjuvant Therapy in Chronic Hepatitis C Patients Not Responding To Interferon. <i>American Journal of Gastroenterology</i> , 1999, 94, 1696-1698.	0.4	22
122	Differential effect of ritonavir and indinavir on immune response to hepatitis C virus in HIV-1 infected patients. <i>Aids</i> , 1999, 13, 1995.	2.2	22
123	Amino-acid change in the Epstein-Barr-virus zebra protein in undifferentiated nasopharyngeal carcinomas from Europe and North Africa. , 1998, 75, 497-503.		30
124	An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 13120-13124.	7.1	266
125	Un inhibiteur de la protéase du VIH modifie la réponse antivirale des lymphocytes T CD8 : nouvelles applications thérapeutiques.. <i>Medecine/Sciences</i> , 1998, 14, 1458.	0.2	0
126	Inhibitory Effects of Specific Apolipoprotein C-III Isoforms on the Binding of Triglyceride-rich Lipoproteins to the Lipolysis-stimulated Receptor. <i>Journal of Biological Chemistry</i> , 1997, 272, 31348-31354.	3.4	66



#	ARTICLE	IF	CITATIONS
127	Selectivity of the major histocompatibility complex class II presentation pathway of cortical thymic epithelial cell lines. <i>European Journal of Immunology</i> , 1997, 27, 855-859.	2.9	31
128	New types of primers (stair primers) for PCR amplification of the variable V3 region of the human immunodeficiency virus. <i>Journal of Virological Methods</i> , 1996, 58, 7-19.	2.1	12
129	SIDA : incertitude ou d'©terminisme. <i>Medecine/Sciences</i> , 1996, 12, 1051.	0.2	0
130	Inhibitory Effect on the Lipolysis-stimulated Receptor of the 39-kDa Receptor-associated Protein. <i>Journal of Biological Chemistry</i> , 1995, 270, 17068-17071.	3.4	24
131	Automated quantitative determination of hepatitis C virus viremia by reverse transcription-PCR. <i>Journal of Clinical Microbiology</i> , 1994, 32, 1887-1893.	3.9	39
132	Cleavage of immunoglobulin A1, A2 and G by proteases from clinical isolates of <i>Pasteurella multocida</i> . <i>Journal of Medical Microbiology</i> , 1992, 37, 128-132.	1.8	15
133	Dermonecrotic toxin production by strains of <i>Pasteurella multocida</i> isolated from man. <i>Journal of Medical Microbiology</i> , 1991, 34, 333-337.	1.8	27
134	Impairment of jacalin binding to serum IgA in IgA nephropathy. <i>Journal of Clinical Laboratory Analysis</i> , 1990, 4, 115-119.	2.1	90
135	Synthesis of digoxigenin-labelled DNA probe by polymerase chain reaction: Application to epstein-barr virus and <i>Chlamydia trachomatis</i> . <i>Research in Virology</i> , 1990, 141, 331-335.	0.7	32
136	Interferon Production in Severe Hemophiliacs with and without HIV Antibodies. <i>Journal of Interferon Research</i> , 1988, 8, 89-94.	1.2	9
137	Investigation of human immune response to <i>Micropolyspora faeni</i> antigens by enzyme-linked immunoelectrodifusion assay and immunoblotting. <i>Journal of Clinical Microbiology</i> , 1988, 26, 443-447.	3.9	15